Title
The BENeFiTS Trial in Beta Thalassemia Intermedia
A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease
Phase
Phase 1/Phase 2Lead Sponsor
Phoenicia BioScienceStudy Type
InterventionalStatus
RecruitingIndication/Condition
Beta Thalassemia Intermedia Sickle Cell DiseaseIntervention/Treatment
Benserazide Only ProductStudy Participants
36Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which delivers oxygen throughout the body.The diseases are characterized by hemolytic anemia, organ damage, and early mortality without treatment. Increases in another type of (normal) hemoglobin, fetal globin (HbF), which is normally silenced in infancy, reduces anemia and morbidity. Even incremental augmentation of fetal globin is established to reduce red blood cell pathology, anemia, certain complications, and to improve survival.
This trial will evaluate an oral drug discovered in a high throughput screen, which increases fetal globin protein (HbF and red blood cells expressing HbF)and messenger ribonucleic acid (mRNA) to high levels in anemic nonhuman primates and in transgenic mice. The study drug acts by suppressing 4 repressors of the fetal globin gene promoter in progenitor cells from patients. The drug has been used for 50 years in a combination product for different actions - to enhance half-life and reduce side effects of a different active drug- and is considered safe for long-term use.
This trial will first evaluate 3 dose levels in small cohorts of nontransfused patients with beta thalassemia intermedia. The most active dose will then be evaluated in larger subject groups with beta thalassemia and other hemoglobinopathies, such as sickle cell disease.
The study will first evaluate 3 doses of the investigational drug which are considered safe with chronic use in a combination therapeutic used widely for a different disease in Europe and Canada. The doses to be studied are human equivalent doses of doses that are active in nonhuman primates in inducing high level fetal globin messenger ribonucleic acid (mRNA), protein, and proportions of red blood cells expressing fetal globin protein (F-cells). Additive effects are observed with hydroxyurea in sickle cell patients' cells in vitro.
The study will first evaluate the study therapeutic in male and female patients who are 18 years and older. After a screening period to obtain baseline medical and laboratory data, the study drug will be taken by mouth once per day, every other day. The first dose will be taken in a clinical unit, and thereafter will be taken at home for 12 weeks. Laboratory tests, physical exams, and tolerability will be assessed 6 times over 4 months, including for one month after completion of dosing.
The cohorts will be enrolled sequentially. Each new cohort will begin after the prior lower dose cohort has received 2 weeks of treatment without serious adverse events related to the study drug. The dose that increases fetal globin assays to the highest degree will be evaluated in a larger group of subjects with beta thalassemia intermedia and a groups with sickle cell disease. Other regimens or test doses may be added as needed to identify an active dose and regimen. The study drug is expected to be safe when added to most other medications used to treat thalassemia.
Investigational drug
A low dose, by mouth, once per day, on Monday, Wednesday, and Friday for 12 weeks
A middle dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 weeks
Highest dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 to 24 weeks
The highest dose, by mouth once per day on 5 days per week for 24 weeks
The most active dose given once per day on the most active regimen for up 24 weeks
Inclusion Criteria: Beta thalassemia intermedia (BTI) or (NTDT, Non-Transfusion Dependent Thalassemia) with at least one documented beta thalassemia mutation, including HbE beta thalassemia or an established diagnosis of sickle cell disease >18 years of age at time of consent Average of 2 total hemoglobin (Hgb) levels between 6.0 and 10.0 g/dL in the preceding 6 months Able and willing to give consent and comply with all study procedures If female and of childbearing potential, must have a documented negative pregnancy test prior to entry and agree to use one or more locally medically accepted methods of contraception Exclusion Criteria: Red blood cell (RBC) transfusion within 2 months prior to administration of study medication Participating in a chronic transfusion program Pulmonary hypertension requiring oxygen therapy Use of erythropoiesis stimulating agents within 90 days of first dose Transaminases > 3 times upper limit of institution normal (ULN) Total and direct bilirubin > 3 times institution ULN unless due solely to hemolysis Known infection with HIV or hepatitis C (untreated) Fever > 38.5°C in the week prior to first administration of study medication History of osteoporosis or osteomalacia with a fragility fracture Received other investigational systemic therapy within 30 days prior to first dose Narrow angle glaucoma Currently pregnant or breast feeding a child Known current drug or alcohol abuse Taking monoamine oxidase inhibitors Other co-morbidity that substantially increases subject risk for the study per Investigator discretion
